Bimekizumab Maintenance of Response through Three Years in Patients With Moderate to Severe Plaque Psoriasis Who Responded at Week 16: Results from the BE BRIGHT Open-Label Extension Trial. J of Skin 2022, 6 (6), s65. https://doi.org/10.25251/skin.6.supp.65.